Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Glomerulonephritis in a 15-Year-Old Patient After Receiving the Second Dose of the BBIBP-CorV (Sinopharm) COVID-19 Vaccine: A Case Report
| Author | Elham Ramezanzade | en |
| Author | Reyhane Ghanbari | en |
| Author | Tina Yazdanipour | en |
| Orcid | Elham Ramezanzade [0000-0001-9415-9319] | en |
| Orcid | Reyhane Ghanbari [0000-0003-3789-4645] | en |
| Orcid | Tina Yazdanipour [0000-0002-6455-4542] | en |
| Issued Date | 2022-08-31 | en |
| Abstract | Introduction: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a group of multisystemic autoimmune diseases that can involve organs such as kidneys and respiratory tracts. Since the initiation of COVID-19 vaccines, there have been few cases of antineutrophil cytoplasmic antibody (ANCA) glomerulonephritis development after receiving vaccine doses. Case Presentation: This report describes a 15-year-old man who has developed ANCA-associated glomerulonephritis (AAGN) after receiving the second dose of BBIBP-CorV (Sinopharm) COVID-19 vaccine. Conclusions: Development of AAGN after both natural SARS-CoV-2 infection and following other vaccinations raises the question of the possible causality between the two. Considering the widespread use of COVID-19 vaccines, it is highly important to investigate their possible side effects. | en |
| DOI | https://doi.org/10.5812/numonthly-127124 | en |
| Keyword | Antineutrophil Cytoplasmic Antibody | en |
| Keyword | Glomerulonephritis | en |
| Keyword | SARS-CoV-2 | en |
| Publisher | Brieflands | en |
| Title | Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Glomerulonephritis in a 15-Year-Old Patient After Receiving the Second Dose of the BBIBP-CorV (Sinopharm) COVID-19 Vaccine: A Case Report | en |
| Type | Case Report | en |